WO2004078169A8 - Use of ep2 selective receptor agonists in medical treatment - Google Patents
Use of ep2 selective receptor agonists in medical treatmentInfo
- Publication number
- WO2004078169A8 WO2004078169A8 PCT/IB2004/000553 IB2004000553W WO2004078169A8 WO 2004078169 A8 WO2004078169 A8 WO 2004078169A8 IB 2004000553 W IB2004000553 W IB 2004000553W WO 2004078169 A8 WO2004078169 A8 WO 2004078169A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- facilitating
- treating
- hypertension
- selective receptor
- occurrence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ541828A NZ541828A (en) | 2003-03-04 | 2004-02-23 | Use of EP2 selective receptor agonists in medical treatment |
MXPA05009398A MXPA05009398A (en) | 2003-03-04 | 2004-02-23 | Use of ep2 selective receptor agonists in medical treatment. |
CA002518193A CA2518193A1 (en) | 2003-03-04 | 2004-02-23 | Use of ep2 selective receptor agonists in medical treatment |
AU2004216898A AU2004216898A1 (en) | 2003-03-04 | 2004-02-23 | Use of EP2 selective receptor agonists in medical treatment |
JP2006506276A JP2006519250A (en) | 2003-03-04 | 2004-02-23 | Use of EP2 selective receptor agonists in medical procedures |
BRPI0408061-0A BRPI0408061A (en) | 2003-03-04 | 2004-02-23 | medical treatment using an ep 2 selective receptor agonist |
EP04713611A EP1601351A1 (en) | 2003-03-04 | 2004-02-23 | Use of ep2 selective receptor agonists in medical treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45188903P | 2003-03-04 | 2003-03-04 | |
US60/451,889 | 2003-03-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004078169A1 WO2004078169A1 (en) | 2004-09-16 |
WO2004078169A8 true WO2004078169A8 (en) | 2005-04-21 |
Family
ID=32962656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2004/000553 WO2004078169A1 (en) | 2003-03-04 | 2004-02-23 | Use of ep2 selective receptor agonists in medical treatment |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1601351A1 (en) |
JP (1) | JP2006519250A (en) |
KR (1) | KR20050105511A (en) |
CN (1) | CN1859903A (en) |
AU (1) | AU2004216898A1 (en) |
BR (1) | BRPI0408061A (en) |
CA (1) | CA2518193A1 (en) |
CL (1) | CL2004000412A1 (en) |
MX (1) | MXPA05009398A (en) |
NZ (1) | NZ541828A (en) |
PL (1) | PL378748A1 (en) |
TW (1) | TW200424176A (en) |
WO (1) | WO2004078169A1 (en) |
ZA (1) | ZA200506532B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
JP4666257B2 (en) * | 2003-07-25 | 2011-04-06 | 小野薬品工業株式会社 | Cartilage-related disease treatment |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
KR101238525B1 (en) | 2004-12-31 | 2013-02-28 | 레디 유에스 테라퓨틱스 인코포레이티드 | Novel benzylamine derivatives as cetp inhibitors |
US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
US7696235B2 (en) * | 2005-08-29 | 2010-04-13 | Allergan, Inc. | EP2 receptor agonists for treating glaucoma |
RU2493252C2 (en) | 2006-03-24 | 2013-09-20 | Чилдрен'З Медикал Сентер Корпорейшн | Method to stimulate expansion of haematopoietic stem cells |
KR101088942B1 (en) | 2006-07-28 | 2011-12-01 | 화이자 프로덕츠 인코포레이티드 | Ep2 agonists |
JP5426389B2 (en) | 2006-10-20 | 2014-02-26 | チルドレンズ メディカル センター コーポレーション | Methods for enhancing tissue regeneration |
US7939671B2 (en) * | 2007-08-21 | 2011-05-10 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
AU2009224329B2 (en) * | 2008-03-12 | 2013-11-07 | Ube Corporation | Pyridylaminoacetic acid compound |
US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
WO2010091052A2 (en) | 2009-02-03 | 2010-08-12 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
CA2757291C (en) | 2009-03-30 | 2017-05-23 | Ube Industries, Ltd. | Medical composition for treatment or prophylaxis of glaucoma |
WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
WO2011030871A1 (en) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | N-substituted heteroaryl compounds |
CA2773998A1 (en) * | 2009-09-11 | 2011-03-17 | Ube Industries, Ltd. | Substituted carbonyl compound |
WO2011030872A1 (en) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | Sulfonamide compounds |
JP2011057633A (en) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | Medicine containing pyridylaminoacetic acid compound |
WO2011030864A1 (en) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | Aniline compounds |
WO2011030865A1 (en) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | Substituted zenzyl compounds |
WO2011030873A1 (en) * | 2009-09-11 | 2011-03-17 | 宇部興産株式会社 | Benzyl compounds |
EP2520570A4 (en) * | 2009-12-25 | 2013-07-17 | Ube Industries | Aminopyridine compound |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
CA2850022C (en) | 2011-09-27 | 2018-05-01 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
EP2804605A4 (en) * | 2012-01-20 | 2015-07-08 | Acucela Inc | Substituted heterocyclic compounds for disease treatment |
WO2014078434A1 (en) * | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Compounds and methods for skin repair |
WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
SG11201507976YA (en) | 2013-03-28 | 2015-10-29 | Ube Industries | Substituted biaryl compound |
AP2016009502A0 (en) | 2014-05-13 | 2016-10-31 | Novartis Ag | Compounds and compositions for inducing chondrogenesis |
CN106397149B (en) * | 2016-08-26 | 2019-05-21 | 大连奇凯医药科技有限公司 | The preparation method of pentafluorobenzaldehyde |
CN115636761A (en) * | 2021-07-20 | 2023-01-24 | 中国石油天然气股份有限公司 | Oil-soluble surfactant, oil displacement agent and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2113787A1 (en) * | 1993-01-29 | 1994-07-30 | Nobuyuki Hamanaka | Carbocyclic sulfonamides |
DK0951282T3 (en) * | 1996-12-20 | 2008-07-14 | Pfizer | Skeletal disease prevention and treatment with EP2 receptor subtype selective prostaglandin E2 agonists |
UA67754C2 (en) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Prostaglandin agonists and use thereof for the treatment of bone disorders |
US6376533B1 (en) * | 2000-10-20 | 2002-04-23 | Allergan Sales, Inc. | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
-
2004
- 2004-02-23 CN CNA2004800085767A patent/CN1859903A/en active Pending
- 2004-02-23 EP EP04713611A patent/EP1601351A1/en not_active Withdrawn
- 2004-02-23 CA CA002518193A patent/CA2518193A1/en not_active Abandoned
- 2004-02-23 MX MXPA05009398A patent/MXPA05009398A/en unknown
- 2004-02-23 JP JP2006506276A patent/JP2006519250A/en not_active Withdrawn
- 2004-02-23 KR KR1020057016414A patent/KR20050105511A/en not_active Application Discontinuation
- 2004-02-23 PL PL378748A patent/PL378748A1/en not_active Application Discontinuation
- 2004-02-23 AU AU2004216898A patent/AU2004216898A1/en not_active Abandoned
- 2004-02-23 NZ NZ541828A patent/NZ541828A/en unknown
- 2004-02-23 WO PCT/IB2004/000553 patent/WO2004078169A1/en active Application Filing
- 2004-02-23 BR BRPI0408061-0A patent/BRPI0408061A/en not_active IP Right Cessation
- 2004-03-01 TW TW093105312A patent/TW200424176A/en unknown
- 2004-03-02 CL CL200400412A patent/CL2004000412A1/en unknown
-
2005
- 2005-08-16 ZA ZA200506532A patent/ZA200506532B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004078169A1 (en) | 2004-09-16 |
AU2004216898A1 (en) | 2004-09-16 |
CL2004000412A1 (en) | 2005-02-04 |
KR20050105511A (en) | 2005-11-04 |
CN1859903A (en) | 2006-11-08 |
TW200424176A (en) | 2004-11-16 |
BRPI0408061A (en) | 2006-02-14 |
PL378748A1 (en) | 2006-05-15 |
JP2006519250A (en) | 2006-08-24 |
CA2518193A1 (en) | 2004-09-16 |
EP1601351A1 (en) | 2005-12-07 |
ZA200506532B (en) | 2007-03-28 |
MXPA05009398A (en) | 2005-12-05 |
NZ541828A (en) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004078169A8 (en) | Use of ep2 selective receptor agonists in medical treatment | |
Della Valle et al. | Surgical exposures in revision total knee arthroplasty | |
WO2007120539A3 (en) | Orthopedic device | |
WO2001050999A3 (en) | Materials and methods for improved bone tendon bone transplantation | |
WO2002087415A3 (en) | Method of applying an active compressive force continuously across a fracture | |
WO2003013342A3 (en) | Materials and methods for improved bone tendon bone transplantation | |
WO2010033702A3 (en) | Intramedullary arthrodesis nail and method of use | |
WO2008005427A3 (en) | Pdgf-biomatrix compositions and methods for treating rotator cuff injuries | |
Masri et al. | Seven specialized exposures for revision hip and knee replacement | |
CN105120774A (en) | Apparatus and method for regeneration of ligaments and tendons | |
Freeland et al. | Malunions of the finger metacarpals and phalanges | |
RU2006126967A (en) | METHOD FOR ARTHRODESIS OF THE ANKLE AND TANTED JOINTS | |
BR0314362A (en) | Method to prevent or reduce secondary fractures after hip fracture | |
Bozkurt et al. | Stability of a cannulated screw versus a Kirschner wire for the proximal crescentic osteotomy of the first metatarsal: a biomechanical study | |
Messer et al. | Thumb metacarpophalangeal joint arthrodesis using the AO 3.0-mm cannulated screw: surgical technique | |
Raja Gopal et al. | Functional outcome of ante grade interlocking intramedullary nailing for humeral shaft fractures | |
De Carolis et al. | A lifelong story: Case report of a humeral shaft nonunion successfully treated after 30 years | |
KR101439944B1 (en) | Tibial tuberosity advancement using hydroxyapatite scaffold in the small animal cranial cruciate ligament rupture | |
Sabat et al. | Late extensor pollicis longus rupture following plate fixation in Galeazzi fracture dislocation | |
RU2423085C2 (en) | Method of endoprosthetics of hip joint in case of high congenital hip dislocation | |
Owusu et al. | Revision of failed distal interphalangeal arthrodesis complicated by retained headless screw | |
Michels et al. | Endoscopic Guided Tibiotalocalcaneal Arthrodesis After Failed | |
RU2587965C1 (en) | Method for osteosynthesis of fractures of distal epimethaphysis of humeral bone and device therefor | |
RU2000103308A (en) | METHOD FOR OSTEOSYNTHESIS OF INJOINT JOINT COMPRESSION FROUSERS OF TYPO condyles under the control of arthroscopy | |
Ghauri et al. | Simple plan of treatment for aseptic non-union of Diaphyseal Fractures of long bones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501597 Country of ref document: PH |
|
WR | Later publication of a revised version of an international search report | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005/06532 Country of ref document: ZA Ref document number: 200506532 Country of ref document: ZA Ref document number: 541828 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 170380 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004216898 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004713611 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518193 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/009398 Country of ref document: MX Ref document number: 1020057016414 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006506276 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004216898 Country of ref document: AU Date of ref document: 20040223 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004216898 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048085767 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057016414 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004713611 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0408061 Country of ref document: BR |